## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.21 indicates fundamental undervaluation. Quality metrics strong (ROE 41%, ROA 13%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($117.55)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. 30,000 Shares in Gilead Sciences, Inc. $GILD Bought by Diadema Partners LP**
- Source: MarketBeat | 20251210T110844 | Bullish | Relevance: 99%
-  Diadema Partners LP recently acquired 30,000 shares of Gilead Sciences, Inc. (NASDAQ: GILD) valued at approximately $3.33 million, making it their 23rd largest holding. This purchase contrasts with recent insider selling activity, where insiders sold 135,757 shares worth about $16.6 million. Gilead Sciences reported strong quarterly earnings, beating estimates and issuing optimistic FY2025 guidance, alongside declaring a quarterly dividend.

**2. Gilead Sciences, Inc. $GILD Shares Sold by Bank of Nova Scotia**
- Source: MarketBeat | 20251209T090829 | Somewhat-Bullish | Relevance: 99%
-  Bank of Nova Scotia significantly reduced its stake in Gilead Sciences (NASDAQ:GILD) by 43.4% in Q2, selling 445,433 shares. This reduction leaves them with 580,217 shares valued at approximately $64.3 million, while institutional investors now collectively own about 83.7% of the stock. Despite insider selling activity, Gilead reported strong Q3 earnings, beating EPS and revenue estimates, and analysts maintain a "Moderate Buy" consensus with an average target price of $130.65.

**3. Who Owns Gilead Sciences? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20251211T130826 | Somewhat-Bullish | Relevance: 99%
-  Gilead Sciences (NASDAQ: GILD) is primarily owned by large passive institutions, providing a stable long-term investment base. While active managers have made selective adjustments, several sophisticated hedge funds like those of Paul Tudor Jones and Jeremy Grantham have significantly increased their positions, suggesting an improving outlook for the company's oncology strategy and long-term earnings. Insider trades, however, remain small and appear to be compensation-related rather than indicative of major directional shifts in executive confidence.

**4. Dymon Asia Capital Singapore PTE. LTD. Purchases Shares of 18,000 Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251210T110803 | Bullish | Relevance: 99%
- Dymon Asia Capital Singapore PTE. LTD. recently acquired 18,000 shares of Gilead Sciences, Inc. (NASDAQ:GILD) valued at approximately $1.996 million, making it their 17th largest holding. Gilead reported strong Q3 earnings, beating EPS and revenue estimates, and announced a quarterly dividend of $0.79 per share. Analysts generally rate Gilead as a "Moderate Buy" with a consensus target price of $130.65, despite recent insider share sales totaling over $16 million.

**5. Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer**
- Source: Business Wire | 20251209T133229 | Bullish | Relevance: 98%
- The Gilead Foundation has announced over $3 million in new grants to enhance education, care, and support services for individuals affected by metastatic breast cancer. This funding, distributed to 53 organizations, builds on over $21 million in support since 2021, aiming to improve access to breast cancer education and care nationwide. The grants will address critical gaps, recognizing that metastatic breast cancer has a five-year relative survival rate of 29%, underscoring the need for improved patient navigation and integrated support services.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $150 | $145 | +3% |
| 2025-11-13 | Needham | $140 | $133 | +5% |
| 2025-11-13 | Scotiabank | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-11-13 | Needham | main | Buy |
| 2025-11-13 | Scotiabank | init | Sector Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($10.00M) |
| Sells | 14 ($7.11M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Insider selling cluster: $7.1M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.21 indicates undervaluation relative to growth. Forward P/E 14.1x stretched relative to 7% growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $152.9B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.21 |
| Forward P/E | 14.1 |
| Current P/E | 15.1 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.8% to -3.2% (+1.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 7.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.6%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.66), momentum weakening. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.16% (CS: 22) | Weak |
| RSI_14 | 51.0 | Neutral |
| MACD Histogram | -0.66 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 1.015x | Above |
| vs SMA200 | 1.089x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $123.21
- **Stop Loss:** $117.55 (4.6% risk)
- **Target:** $134.53 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 243
- **Position Value:** $29,940.03
- **Portfolio %:** 29.94%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*